Elmind Capital LP

Elmind Capital provides discretionary investment management to private pooled funds through a master‑feeder structure, serving accredited and qualified investors rather than individual retail clients. The firm manages assets on behalf of feeder funds that invest substantially all capital in a Cayman‑domiciled master fund and does not tailor the Funds’ strategies to individual investors.

Elmind Capital pursues a long/short equity strategy with a deep fundamental, bottom‑up research process concentrated in small‑ and mid‑capitalization biotechnology and life sciences companies, emphasizing scientific and clinical catalysts. The firm employs leverage and derivatives for hedging and risk management and may allocate a limited portion of assets to opportunistic illiquid or private “special situation” biotech investments.

What is noteworthy about the firm is its concentrated sector focus and an explicit policy permitting up to a modest percentage of fund assets in illiquid or private special situations, combined with rapid institutional asset growth since formation despite having no long operating history. The firm operates under a key‑person model, makes use of alternative data and third‑party research (including soft‑dollar arrangements), and may provide preferential terms or side‑letter arrangements to certain investors, which can affect allocations among accounts.